Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future, is a strategic resource exploring how U.S. drug pricing could change if new international reference pricing (IRP) policies take hold. Using a sample portfolio, we model potential impacts across multiple scenarios to help market access teams prepare for what may come next.

Understanding the Evolving IRP Landscape

A May 2025 Executive Order has reignited the debate around MFN pricing, with the potential to tie US drug prices to what other high-income countries pay. This isn’t just policy speculation, it’s a regulatory shift that could fundamentally alter pharmaceutical economics worldwide.

The concept isn’t new. Previous MFN proposals faced significant legal challenges, but the current political climate and growing pressure on drug prices have brought International Reference Pricing (IRP) back into sharp focus. The difference now? The potential for implementation feels more real than ever.

For market access teams, this represents uncharted territory. How do you prepare for a policy that could reshape everything from launch sequencing to pricing strategies? How do you model impacts when the implementation details remain unclear?

Hear from the experts behind Access Infinity

Access Infinity’sinsights, taken from years of working with top-tier pharma companies and deep regulatory analysis, paint a clearer picture of what IRP implementation could mean for the industry. Our experts break down the May 2025 Executive Order and modelled its potential impacts across different implementation pathways.

What the analysis will cover

The analysis addresses some of the most pressing questions facing market access teams today, including:

Breaking down the executive order and its implications
Two critical scenarios for IRP implementation
Real portfolio impact modelling with patient cost analysis
Strategic responses for manufacturers and payers
Launch sequencing strategies to protect pricing power
Long-term implications for global pharmaceutical markets

Why scenario planning matters now

While regulatory uncertainty has always been part of pharmaceutical strategy, the potential for International Reference Pricing and MFN policy implementation represents a paradigm shift that demands immediate attention. So how can market access teams prepare for multiple outcomes and position themselves strategically?

Historically, while teams have planned for incremental policy changes, MFN pricing could fundamentally alter the economics of pharmaceutical innovation. Our new analysis showcases exactly why scenario-based planning is essential, helping teams prepare for disruption while identifying opportunities within regulatory change.

The analysis reveals that smart strategic positioning today could mean the difference between protecting market position and facing significant revenue erosion. From launch sequencing tactics to pricing optimisation strategies, there has never been a more crucial time to think ahead of regulatory change.

Likewise, understanding both the direct-to-consumer and channel disruption scenarios gives market access teams the competitive advantage they need. This analysis shows how to navigate uncertainty while maintaining strategic flexibility for whatever emerges.

Download the analysis today

‘Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future’ is essential reading for market access teams that want to stay ahead of regulatory change. It comes as just one of many expert resources from Access Infinity, including our ‘Market Access Matters’ podcast. You can also find out more in our on-demand webinars.

Gain deeper insights and plan for an uncertain but strategic future. Fill out the form below to receive your copy.

Download the resource

Navigating MFN Drug Pricing Reform

Add Your Heading Text Here